Benzimidazole inhibition of biofilm formation

1. A compound comprising:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, aryloxy, heteroaryloxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, acyl, acylamino, amino, alkylamino, dialkylamino, acylamino, carboxylate (—CO 2 H), cyano, nitro, —CONH 2 , heteroarylamino, oxime, alkyloxime, aryloxime, amino-oxime or halogen when A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q are carbon, and X is O, NR (where R is hydrogen, alkyl, aryl or acyl), S, SO (sulfoxide), SO 2 (sulfone), or C(R) 2 (where R═H, alkyl, aryl, alkenyl, alkynyl, or acyl); or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently hydrogen or hydroxyl when A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q are each independently nitrogen, and

combinations, pharmaceutically acceptable salts, esters, and prodrugs thereof.

2. A composition comprising a compound of claim 1 and a carrier.

3. A medical device comprising one or more compounds of the following formula:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, aryloxy, heteroaryloxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, acyl, acylamino, amino, alkylamino, dialkylamino, arylamino, carboxylate (—CO 2 H), cyano, nitro, CONH 2 , heteroarylamino, oxime, alkyloxime, aryloxime, amino-oxime or halogen when A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q are carbon, and X is O, NR (where R is hydrogen, alkyl, aryl or acyl), S, SO (sulfoxide), SO 2 (sulfone), or C(R) 2 (where R═H, alkyl, aryl, alkenyl, alkynyl, or acyl); or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently hydrogen or hydroxyl when A, B, C, D, E, F; G, H, I, J, K, L, M, N, O, P, and Q are each independently nitrogen,

and combinations, pharmaceutically acceptable salts, esters, and prodrugs thereof.

4. A method of treating an infection by a pathogen comprising administering to a mammal infected with the pathogen a compound of the following formula:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, alkoxy, aryloxy, heteroaryloxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, acyl, acylamino, amino, alkylamino, dialkylamino, arylamino, carboxylate (−CO 2 H), cyano, nitro, CONH 2 , heteroarylamino, oxime, alkyloxime, aryloxime, amino-oxime or halogen when A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q are carbon, and X is O, NR (where R is hydrogen, alkyl, aryl or acyl), S, SO (sulfoxide), SO 2 (sulfone), or C(R) 2 (where R═H, alkyl, aryl, alkenyl, alkynyl, or acyl); or wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently hydrogen or hydroxyl when A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, and Q are each independently nitrogen,

and combinations, pharmaceutically acceptable salts, esters, and prodrugs thereof.

5. The method of claim 4 , wherein the compound or a combination thereof is administered topically or locally.

6. The method of claim 4 , wherein the compound or a combination thereof is administered to the site of an infection.

7. The method of claim 4 , wherein the pathogen is a gram negative bacterium.

8. The method of claim 4 , wherein the pathogen is a gram positive bacteria.

9. The method of claim 4 , wherein the pathogen is a drug-resistant pathogen.

10. The method of claim 4 , wherein the pathogen is selected from Vibrio cholerae, P. aeruginosa, Klebsiella pneumoniae, Erwinia amylovora, Shigella boydii, Staphylococcus aureus and combinations thereof.

11. The method of claim 4 , wherein the infection by a pathogen is related, or leads, to endocarditis, otitis media, chronic prostatitis, periodontal disease, chronic urinary tract infection, cystic fibrosis, an infection on an indwelling medical device, or a chronic non-healing wound.

12. The method of claim 4 , wherein a therapeutically effective amount is administered.

13. The method of claim 12 , wherein a therapeutically effective amount is an amount effective to inhibit biofilm formation by the pathogen.

14. A method of inhibiting biofilm formation in biofilm-forming pathogens comprising contacting the pathogen with the compound of claim 1 to thereby inhibit biofilm formation of the pathogen.

15. The method of claim 14 , wherein contacting comprises administering or applying the compound to a surface suspected of containing the pathogen.